Similar articles for PMID: 29277808

Year	Number of Results
2009	1
2010	5
2011	4
2012	9
2013	25
2014	34
2015	28
2016	43
2017	39
2018	38
2019	26
2020	17
2021	15
2022	6
2023	1
2024	0

1

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.

Poprach A, Fiala O, Chloupkova R, Melichar B, Lakomy R, Petrakova K, Zemanova M, Kopeckova K, Slaby O, Studentova H, Kopecký J, Kiss I, Finek J, Dusek L, Buchler T. Poprach A, et al. Anticancer Res. 2018 Jan;38(1):449-456. doi: 10.21873/anticanres.12243. Anticancer Res. 2018. PMID: 29277808

2

Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.

Xie M, He CS, Huang JK, Lin QZ. Xie M, et al. Eur J Cancer. 2015 Mar;51(5):595-603. doi: 10.1016/j.ejca.2015.01.005. Epub 2015 Jan 21. Eur J Cancer. 2015. PMID: 25618828 Clinical Trial.

3

Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.

Hainsworth JD, Rubin MS, Arrowsmith ER, Khatcheressian J, Crane EJ, Franco LA. Hainsworth JD, et al. Clin Genitourin Cancer. 2013 Sep;11(3):270-5. doi: 10.1016/j.clgc.2013.04.006. Epub 2013 May 9. Clin Genitourin Cancer. 2013. PMID: 23665131 Clinical Trial.

4

A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.

Kim MJ, Park SH, Lee JL, Lee SH, Lee SJ, Lim HY. Kim MJ, et al. BMC Urol. 2016 Aug 2;16(1):46. doi: 10.1186/s12894-016-0163-5. BMC Urol. 2016. PMID: 27484998 Free PMC article.

5

Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.

Rautiola J, Utriainen T, Peltola K, Joensuu H, Bono P. Rautiola J, et al. Acta Oncol. 2014 Jan;53(1):113-8. doi: 10.3109/0284186X.2013.794957. Epub 2013 May 30. Acta Oncol. 2014. PMID: 23721300 Clinical Trial.

6

Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.

Iacovelli R, Massari F, Albiges L, Loriot Y, Massard C, Fizazi K, Escudier B. Iacovelli R, et al. Eur Urol. 2015 Jul;68(1):154-60. doi: 10.1016/j.eururo.2014.10.034. Epub 2014 Nov 6. Eur Urol. 2015. PMID: 25466943

7

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID. Sternberg CN, et al. Eur J Cancer. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010. Epub 2013 Jan 12. Eur J Cancer. 2013. PMID: 23321547 Clinical Trial.

8

Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.

Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Matrana MR, et al. BJU Int. 2016 Aug;118(2):264-71. doi: 10.1111/bju.13374. Epub 2015 Dec 13. BJU Int. 2016. PMID: 26573089 Free PMC article.

9

[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].

Maráz A, Bodrogi I, Csejtei A, Dank M, Géczi L, Küronya Z, Mangel L, Petrányi A, Szûcs M, Bodoky G. Maráz A, et al. Magy Onkol. 2013 Sep;57(3):173-6. Epub 2013 Aug 9. Magy Onkol. 2013. PMID: 24107823 Free article. Hungarian.

10

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.

Buchler T, Bortlicek Z, Poprach A, Pavlik T, Veskrnova V, Honzirkova M, Zemanova M, Fiala O, Kubackova K, Slaby O, Svoboda M, Vyzula R, Dusek L, Melichar B; Czech Renal Cancer Cooperative Group. Buchler T, et al. Eur Urol. 2016 Sep;70(3):469-75. doi: 10.1016/j.eururo.2015.12.031. Epub 2015 Dec 30. Eur Urol. 2016. PMID: 26746623

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

241 results

Results by year